<DOC>
	<DOCNO>NCT00727922</DOCNO>
	<brief_summary>Oxaliplatin major antitumor agent use limit potentially disable neurotoxicity , characterize sensitive defect extremities.Mangafodipir MRI contrast agent antioxidant property . Our previous laboratory work show mangafodipir able prevent hematologic toxicity several chemotherapy agent , include oxaliplatin increase antitumor activity . Preliminary clinical data suggest mangafodipir could prevent oxaliplatin neurotoxicity.The primary purpose present study assess protective effect mangafodipir patient already moderate oxaliplatin neuropathy continuation treatment desirable significant antitumor effect .</brief_summary>
	<brief_title>Protective Effect Mangafodipir Against Oxaliplatin Neurotoxicity</brief_title>
	<detailed_description>Phase 2 study aim assess protective effect mangafodipir oxaliplatine neuropathy.Population : Cancer patient mild ( grade 2 ) oxaliplatin neuropathy continuation oxaliplatin least 4 infusion desirable include , whatever location primitive tumor use others anticancer agents.Treatment : Mangafodipir ( 0.5 ml/kg ) administer 30 minute infusion administration oxaliplatin . The oxaliplatin dose ( 85 100 mg/mÂ² ) length infusion ( 2 hour ) inclusion modification authorize study participation . Primary objective : Neuropathy clinically evaluate accord NCI-CTC criterion mangafodipir oxaliplatin thereafter one month last infusion . The primary criterion bad grade oxaliplatin neuropathy experienced patient . The improvement neuropathy define decrease least one grade severity neuropathy least 2 month . Hypothesis : least 50 % patient experience improvement stabilization oxaliplatin neuropathy receive mangafodipir - oxaliplatin association.Treatment discontinuation : treatment stop neuropathy worsen least one grade , case tumor progression , intolerable toxicity , patient wish . Number patient : determine accord simplify Gehan procedure : The inclusion stop objective response ( neuropathy improvement ) observe among first 9 evaluable patient . If least one response observe , 16 evaluable patient include . The total number patient 9 30 patient , include non evaluable patient . Pharmacokinetic : Serum intra- erythrocyte manganese concentration evaluate mangafodipir infusion order detect accumulation Pharmacodynamic : plasmatic total antioxidant activity , superoxide dismutase activity lipid peroxidation assess first cycle : administration oxaliplatin perfusion mangafodipir .</detailed_description>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Edetic Acid</mesh_term>
	<mesh_term>Pyridoxal Phosphate</mesh_term>
	<criteria>NCI CTC grade 2 neuropathy induce oxaliplatine At least 18 year old ECOG PS : 2 less Life expectancy longer 3 month Written inform consent Adequate hematologic , liver renal function Known hypersensibility oxaliplatine Cancer resistant oxaliplatine Fertile woman man willing use adequate contraception Pregnant lactate woman Vitamin B6 administration within 48h prior mangafodipir administration Uncontrolled infection Treatment investigational agent , participation another clinical trial within 3 week prior first administration mangafodipir Evidence disease condition contraindicate use investigational drug No Social Security insurance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Neuropathy</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Mangafodipir</keyword>
</DOC>